Advanced protein glycosylation in diabetes and aging

M. Brownlee

Research output: Contribution to journalReview articlepeer-review

1173 Scopus citations


Products of advanced protein glycosylation (advanced glycation end products, or AGEs) accumulate in tissues as a function of time and sugar concentration. AGEs induce permanent abnormalities in extracellular matrix component function, stimulate cytokine and reactive oxygen species production through AGE-specific receptors, and modify intracellular proteins. Pharmacologic inhibition of AGE formation in long-term diabetic animals prevents diabetic retinopathy, nephropathy, neuropathy, and arterial abnormalities in animal models. Clinical trials in humans are currently in progress.

Original languageEnglish (US)
Pages (from-to)223-234
Number of pages12
JournalAnnual Review of Medicine
StatePublished - 1995


  • Advanced glycation end products
  • Aminoguanidine
  • DNA
  • Matrix
  • Mitogens
  • Receptors

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'Advanced protein glycosylation in diabetes and aging'. Together they form a unique fingerprint.

Cite this